DFS analysis observed that high expression of HNRNPA2B1 in three cancers resulted in cancer progression, including CESC, LIHC, ACC, and low expression of HNRNPA2B1 in OV with cancer progression (Supplementary figure 1, Supplementary table 4). This evidence concerns the gene HNRNPA2B1 and adrenal cortex carcinoma.